Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2) 2025-09-18 12:00
Neuronata-R® Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway 2025-09-18 10:28
CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025 2025-09-18 08:15
Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025 2025-09-18 07:30
MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine. 2025-09-18 05:09
Mabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular Disorders 2025-09-17 20:00
Alteogen Receives European Commission Approval for Aflibercept Biosimilar, EYLUXVI® (ALT-L9) 2025-09-17 15:40
111, Inc. Announces Second Quarter 2025 Unaudited Financial Results 2025-09-17 14:00
Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK) 2025-09-17 12:00
Kexing Biopharm's Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF 2025-09-17 10:30
Ascletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting 2025-09-17 07:30
Lunit Showcases AI-Powered Cancer Ecosystem at APEC High-Level Meeting on Health and the Economy and World Bio Summit 2025 2025-09-16 21:00
Akeso's Ligufalimab (CD47 mAb) Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia (AML) 2025-09-16 10:27
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025 2025-09-16 09:00
HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor 2025-09-15 21:30
EmeTerm Wearable Device Under Clinical Study at Ohio State Wexner Medical Center Shows Promise for Chronic Nausea Patients 2025-09-15 21:00
Korea reinforces biopharma leadership at Global Bio Conference 2025 2025-09-15 20:30
Sunsred Launches FDA-cleared Red Light Therapy Devices for Wellness Brands Worldwide 2025-09-15 19:00
Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma 2025-09-15 12:11
Phrontline Biopharma Announces First Patient Dosed in Phase 1 Clinical Trial of TJ101 2025-09-15 08:00